Aztron MedTech Achieves Major Milestones: FDA Listed and $2.5M Seed+ Funding Raised

Aztron MedTech Achieves Major Milestones: FDA Listed and $2.5M Seed+ Funding Raised

July 30, 2025 | San Francisco, CA – Aztron MedTech is proud to announce two pivotal milestones in our journey to transform soft tissue repair:

• FDA listed for the minimally invasive surgical device—the TendMIN™ Telescoping Needle and Grasper, and

• A successful $2.5 million Seed+ funding round to accelerate product development and commercial growth.

These achievements mark a major step forward in our mission to improve outcomes in soft tissue procedures through precision, access, and innovation.

Fueling the Future: $2.5M in Seed+ Funding

Our Seed+ round, led by prominent angel syndicates and joined by Wistron Ventures, brings Aztron’s total funding to $2.5 million. This strategic capital will enable Aztron to:

• Expand clinical studies and deepen collaborations with orthopedic surgeons

• Finalize product development and scale manufacturing

• Launch go-to-market initiatives across the U.S. and globally

• Grow our cross-functional teams in the U.S. and Asia

FDA Greenlight: TendMIN™ System Listed.

In March 2025, Aztron received FDA listed for the TendMIN™ Telescoping Needle , designed for acute mid-substance Achilles tendon ruptures.

With the TendMIN™ Grasper, the TendMIN™ system allows surgeons to perform suture-based repairs through smaller incisions, preserving the paratenon and potentially reducing risk of infection or nerve injury—key benefits over traditional open or percutaneous techniques.

• TendMIN™ Telescoping Needle: Ultrasound-guided, steerable, and designed for precise suture delivery

• TendMIN™ Grasper: Low-profile, articulating tool for safe suture retrieval with minimal tissue disruption

With no capital equipment required, the system seamlessly integrates into existing OR workflows—streamlining procedures and enhancing patient recovery.

What’s Next for Aztron Medtech

With FDA listing secured and strong investor support, Aztron is positioned to scale—driven by a clear mission: to redefine minimally invasive tendon repair by streamlining complex procedures, enhancing clinical outcomes, and improving the surgeon experience.